YCharOS Continues to Expand Industry Advisory Board and Releases New Open Data
— Dr. Aled Edwards
TORONTO AND MONTREAL, ONTARIO, CANADA, Sept. 13, 2022/EINPresswire.com/ — YCharOS Inc., an open science company whose mission is to characterize commercially available antibody reagents for all human proteins, is pleased to announce the continued expansion of its Industry Advisory Committee (IAC).
YCharOS is excited to welcome Cellular Signaling Technology (CST) to the IAC. They join leading antibody manufacturers and cell line providers Abcam, ABclonal Technology, Aviva Systems Biology, Bio-Techne, Developmental Studies Hybridoma Bank (DSHB), GeneTex, Horizon Discovery (a PerkinElmer company), Institute for Protein Innovation (IPI ), Proteintech, Synaptic Systems and Thermo Fisher Scientific.
Current IAC members represent 28% of all antibodies listed in The Antibody Registry and 62% of all antibody citations in research published in 2021 according to CiteAb.
The role of the IAC is to support YCharOS by enabling antibody users, funders and the wider scientific community to better evaluate commercially available antibody reagents and associated knockout cell lines. . The IAC will help guide the YCharOS team to become the world’s leading source of independent, open-source antibody characterization data.
Additionally, YCharOS announces the release of new open science data. The current results, for antibodies targeting 47 proteins relevant to neurology and pharmacology, have been published on Zenodo, the open science platform operated by CERN. Antibodies were tested for Western blot (WB), immunoprecipitation (IP), and immunofluorescence (IF) applications.
“CST’s participation in the IAC further enhances the quality of the data we produce,” said YCharOS Chairman of the Board, Dr. Aled Edwards. “They are a fantastic addition to the committee.”
“The addition of CST is further validation of the value we bring to our IAC partner companies,” said Chetan Raina, CEO of YCharOS. “The partnership with YCharOS reinforces CST’s commitment to the scientific community to generate and sell only the highest quality products.”
Identifying the appropriate antibody for an experiment is a significant challenge for researchers and lies at the heart of the reproducibility crisis seen in biomedical research. To address this unmet need, YCharOS performs direct comparisons of commercially available antibodies against the same target protein and publishes the results transparently and openly.
Companies or researchers interested in supporting our work are encouraged to contact YCharOS.
Cell Signaling Technology: www.cellsignal.com
Aviva Systems Biology: www.avivasysbio.com
ABclonal technology: www.abclonal.com
Developmental Studies Hybridoma Bank: https://dshb.biology.uiowa.edu
Discovery of Horizon: www.horizondiscovery.com
Institute for Protein Innovation (IPI): www.proteininnovation.org
Synaptic systems: www.sysy.com
Thermo Fisher Scientific: www.thermofisher.com
Notes to Editors
About cell signaling technology
Cell Signaling Technology (CST) is a different type of life science company, founded, owned and led by active researchers, with the highest standards in product and service quality, technological innovation and of scientific rigor. Founded in 1999 and based in Danvers, Massachusetts, USA, CST employs more than 500 people worldwide. The company consistently provides scientists around the world with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a dedication to facilitating good science – a company committed to doing the right thing for its customers, communities and our planet.
Rebecca J. Reppucci
Senior Director, Global Marcomm & Technology
Cell Signaling Technology, Inc.
About YCharOS Inc.
YCharOS Inc. (Antibody Characterization through Open Science) is a Canadian open science public benefit company whose mission is to characterize commercially available antibody reagents for all human proteins. All scientific methods and results of YCharOS are transparent and patent-free. The antibody characterization platform industrializes the rigorous methodology established at the Montreal Neurological Institute of McGill University, in collaboration with the Structural Genomics Consortium. Technology commercialization work at McGill University is partially funded by Genome Canada, Genome Quebec and Ontario Genomics through their GAPP program. The company is 100% owned by the Agora Open Science Trust, a registered charity.
For more information, visit www.ycharos.com.
write to us here